FDA Commissions Study on Its Safety Record

After a series of flubs -- most recently, the pulling of Vioxx off the market after studies showed it doubled the risk of heart attack and stroke -- the U.S. Food and Drug Administratin has asked the Institute of Medicine to study the agency's safety monitoring of medicines already on the market.